| Bioactivity | Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1]. |
| Invitro | Prasinezumab 针对人 α-突触核蛋白羧基末端的表位。 Prasinezumab 以高亲和力与人类聚集的 α-突触核蛋白结合[1]。 |
| Name | Prasinezumab |
| CAS | 1960462-19-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407. |